153 related articles for article (PubMed ID: 32017134)
21. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.
Fukuhara K; Ikawa K; Morikawa N; Kumagai K
J Clin Pharm Ther; 2008 Dec; 33(6):677-84. PubMed ID: 19138246
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of methotrexate in Indian cancer patients.
Nagulu M; Kiran VU; Nalini Y; Reddy YN; Krishna DR
Asian Pac J Cancer Prev; 2010; 11(2):403-7. PubMed ID: 20843124
[TBL] [Abstract][Full Text] [Related]
23. Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma.
Hui KH; Chu HM; Fong PS; Cheng WTF; Lam TN
J Clin Pharmacol; 2019 Apr; 59(4):566-577. PubMed ID: 30556906
[TBL] [Abstract][Full Text] [Related]
24. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase.
Taylor ZL; Mizuno T; Punt NC; Baskaran B; Navarro Sainz A; Shuman W; Felicelli N; Vinks AA; Heldrup J; Ramsey LB
Clin Pharmacol Ther; 2020 Sep; 108(3):635-643. PubMed ID: 32558929
[TBL] [Abstract][Full Text] [Related]
25. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.
Rousseau A; Sabot C; Delepine N; Delepine G; Debord J; Lachâtre G; Marquet P
Clin Pharmacokinet; 2002; 41(13):1095-104. PubMed ID: 12403645
[TBL] [Abstract][Full Text] [Related]
26. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
Chládková J; Hak J; Martínková J; Chládek J
Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
[TBL] [Abstract][Full Text] [Related]
27. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
28. The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group.
Beechinor RJ; Thompson PA; Hwang MF; Vargo RC; Bomgaars LR; Gerhart JG; Dreyer ZE; Gonzalez D
Clin Pharmacokinet; 2019 Jul; 58(7):899-910. PubMed ID: 30810947
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetic study of delayed methotrexate excretion in children with acute lymphoblastic leukemia
.
Zang YN; Wang SZ; Qin Y; Zhang JR; Zhao LB; Wang XL
Int J Clin Pharmacol Ther; 2019 Aug; 57(8):402-407. PubMed ID: 31232278
[TBL] [Abstract][Full Text] [Related]
30. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias.
Periclou AP; Avramis VI
Cancer Chemother Pharmacol; 1996; 39(1-2):42-50. PubMed ID: 8995498
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?
Martelli N; Mathieu O; Margueritte G; Bozonnat MC; Daurès JP; Bressolle F; Hillaire-Buys D; Peyrière H
J Clin Pharm Ther; 2011 Apr; 36(2):237-45. PubMed ID: 21366654
[TBL] [Abstract][Full Text] [Related]
32. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetic analyses of methotrexate in pediatric patients: a systematic review.
Cheng Y; Zhang Y; Zhang Y; Liu M; Zhao L
Eur J Clin Pharmacol; 2024 Jul; 80(7):965-982. PubMed ID: 38498098
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters.
Nader A; Zahran N; Alshammaa A; Altaweel H; Kassem N; Wilby KJ
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):221-228. PubMed ID: 27059845
[TBL] [Abstract][Full Text] [Related]
35. Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients.
Wang Z; Zhang N; Chen C; Chen S; Xu J; Zhou Y; Zhao X; Cui Y
Curr Drug Metab; 2019; 20(7):592-600. PubMed ID: 31267867
[TBL] [Abstract][Full Text] [Related]
36. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma.
Pai MP; Debacker KC; Derstine B; Sullivan J; Su GL; Wang SC
Pharmacotherapy; 2020 Apr; 40(4):308-319. PubMed ID: 32090349
[TBL] [Abstract][Full Text] [Related]
38. ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis.
Kim IW; Yun HY; Choi B; Han N; Park SY; Lee ES; Oh JM
Clin Ther; 2012 Aug; 34(8):1816-26. PubMed ID: 22796246
[TBL] [Abstract][Full Text] [Related]
39. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.
Wright KD; Panetta JC; Onar-Thomas A; Reddick WE; Patay Z; Qaddoumi I; Broniscer A; Robinson G; Boop FA; Klimo P; Ward D; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 2015 Jan; 75(1):27-35. PubMed ID: 25342291
[TBL] [Abstract][Full Text] [Related]
40. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.
Hegyi M; Gulácsi A; Cságoly E; Csordás K; Eipel OT; Erdélyi DJ; Müller J; Nemes K; Lautner-Csorba O; Kovács GT
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1697-702. PubMed ID: 22652833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]